New Alzheimer's drug AK152 enters first human safety tests

NCT ID NCT07301502

Not yet recruiting Disease control Sponsor: Akeso Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 1 trial tests a new drug called AK152 in healthy volunteers and people with Alzheimer's disease. The main goal is to check if it is safe and tolerable, and to see how the body processes it. The study is small and early-stage, so it will not prove whether the drug works for Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

AK152

What this could lead to

If successful, this could point toward a new treatment option for Alzheimer's disease that may help control symptoms or slow progression.

What could go wrong

This is a very early Phase 1 trial focused on safety, not effectiveness. It is small and may not show any benefit. Side effects are unknown.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The Frist Affiliated Hospital of USTC

    Hefei, Anhui, China